Omeros Corporation (OMER) Q4 2021 Earnings Call

Investor webinar replay

Meeting Overview The earnings call for Omeros Corporation discussed the company's financial results for the fourth quarter and year-end of 2021, including the strategic divestiture of its ophthalmic product, Omidria. Key updates included financial performance metrics, future expectations for Omidria sales, and ongoing legislative efforts related to pain management. Key Discussion Points - Overview of the fourth quarter and year-end financial results for 2021. - Strategic divestiture of Omidria to Raynor Surgical, including financial implications. - Cash received from the divestiture and future milestone payments. - Performance metrics for Omidria sales and expectations for growth in 2022. - Discussion on the No Pain Act and its potential impact on non-opioid pain management. Decisions Made - No explicit decisions recorded. Action Items & Next Steps - [Unassigned] : Monitor the progress of the No Pain Act and its implications for the company. - [Unassigned] : Prepare for the potentia...

Watch the replay

Replay transcript excerpt

[Speaker identities could not be resolved; generic labels used] [00:00] Speaker 1: Good afternoon and welcome to today's earnings call for Omeros Corporation. [00:04] Speaker 1: At this time all participants are in a listen-only mode. After the company's remark we will conduct a question and answer session. [00:11] Speaker 1: Please be advised that this call is being recorded at the company's request and a replay will be available on the company's website for 1 week from today. [00:20] Speaker 1: I'll turn over the call to Jennifer Williams, Investor Relations for Omeros. [00:26] Speaker 2: Good afternoon and thank you for joining the call today. I'd like to remind you that some of the statements that will be made on the call today will be forward-looking. [00:34] Speaker 2: These statements are based on management's beliefs and expectations as of today only and are subject to change. [00:40] Speaker 2: All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. [00:46] Speaker 2: Please refer to the special note regarding forward-looking statements and the risk factors section in the company's annual report on Form 10-K, which was filed today with the SEC for a discussion of these risks and uncertainties. [00:58] Speaker 2: Today's call will include a discussion of certain non-GAAP financial measures. A reconciliation of these non-GAAP measures to the corresponding GAAP measures is included with OMERIS's earnings plus press release included, [01:10] Speaker 2: excuse me, issued earlier today which is available on the investor relations page of our website and has been furnished with the Form 8K we filed with the SEC earlier today. [01:20] Speaker 2: Now I would like to turn the call over to Dr. G...